BFH772 (VEGFR2 inhibitor): Technical Use, Protocols, and QC Guidance

What This Product Solves

BFH772 (VEGFR2 inhibitor) is designed for laboratory workflows requiring precise inhibition of VEGFR2 kinase activity, a key mediator in the vascular endothelial growth factor (VEGF) signaling axis. Its high selectivity and nanomolar potency (IC50 = 3 nM) make it particularly suited for research into the molecular regulation of angiogenesis, with direct application in tumor angiogenesis models and VEGFR2 pathway interrogation (product_spec). BFH772 is not appropriate in experimental settings where broad kinase inhibition or aqueous solubility is essential, as its activity against off-target kinases is minimal and it is insoluble in water (internal_article). Researchers seeking a tool compound for dissecting VEGFR2-driven processes, without confounding off-target effects, will find BFH772 a strong fit.

Protocol Parameters

• In vitro VEGFR2 kinase inhibition assay | IC50 = 3 nM | Use for quantitative VEGFR2 inhibition screens | Provides high-affinity, selective inhibition for pathway dissection | product_spec (link)
• Solubility in DMSO | ≥53.4 mg/mL | Formulate high-concentration stock solutions for cell-based or biochemical assays | Maximizes working concentration flexibility for titration studies | product_spec
• Long-term stock solution storage | Not recommended | Prepare fresh working solutions before each experiment | Prevents compound degradation and ensures reproducibility | product_spec
• Oral administration in animal models | Dose: workflow-dependent (recommend pilot titration) | Use in tumor angiogenesis inhibition studies | Supported by in vivo activity in animal tumor models; follow local animal care protocols | workflow_recommendation
• Purity specification | >96% | Use for experiments requiring high chemical purity | Minimizes variability from impurities in sensitive kinase assays | product_spec

Workflow Setup and QC Checklist

For best results with BFH772, adhere to the following workflow setup and quality control (QC) steps:

1. Stock Preparation: Dissolve BFH772 in DMSO or ethanol according to solubility limits (DMSO: ≥53.4 mg/mL; ethanol: ≥15.33 mg/mL). Avoid water-based solvents due to insolubility (internal_article).
2. Aliquoting: Prepare single-use aliquots to prevent freeze-thaw cycles, minimizing compound degradation.
3. Storage: Store dry compound and solutions at -20°C. Do not store working solutions long-term; prepare fresh before each use.
4. Quality Verification: Check certificate of analysis and purity (>96%) upon receipt. Validate batch consistency if using in multi-phase studies.
5. Assay Controls: Include vehicle (DMSO or ethanol) controls in all experiments to account for solvent effects.
6. Dosing in Vivo: For animal studies, pilot dose titrations are recommended, referencing prior in vivo tumor growth inhibition performance (source: product_spec).

Common Failure Modes and Fixes

• Poor dissolution or precipitation in assay: Ensure use of DMSO or ethanol at recommended concentrations; vortex and sonicate if needed. Avoid attempts to dissolve in aqueous buffer as compound is water-insoluble.
• Loss of activity upon storage: Discard old or repeatedly thawed stock solutions. Prepare fresh working solutions from dry stock for each assay run.
• Unexpected off-target effects: Verify experimental design does not require broad-spectrum kinase inhibition; BFH772 is highly selective and is not suitable for multi-kinase target studies.
• Low reproducibility between batches: Always confirm batch purity and consult the provided certificate of analysis. For critical studies, re-validate activity with a standard VEGFR2 kinase assay.

Scope and Limitations

BFH772 is optimized for applications requiring high selectivity in VEGFR2-mediated angiogenesis research, such as tumor angiogenesis models and targeted VEGFR2 pathway studies. It is not appropriate for workflows necessitating water-soluble compounds or inhibition of a broad kinase spectrum, as its solubility is strictly limited to DMSO and ethanol and its kinase selectivity profile is narrow (internal_article). Protocols demanding long-term solution storage, or those that cannot accommodate organic solvents, should not use BFH772. Use in clinical or diagnostic applications is not supported by the product specification.

Conclusion

In summary, BFH772 (VEGFR2 inhibitor) is a practical, well-characterized tool for research into VEGFR2-driven angiogenesis, especially where precise pathway interrogation is required. Its high selectivity and nanomolar potency support clear mechanistic studies in tumor models and cell-based assays. Researchers are advised to adhere strictly to recommended solvent, storage, and QC protocols to maximize reproducibility and data integrity. For additional practical guidance, see internal articles such as Technical Guidance for Angiogenesis Research and Protocols & Practical Use in Research, which expand on protocol setup and compound handling best practices.